Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5

被引:147
作者
Parker, CE
Deterding, LJ
Hager-Braun, C
Binley, JM
Schülke, N
Katinger, H
Moore, JP
Tomer, KB
机构
[1] NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA
[2] Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA
[3] Progen Pharmaceut Inc, Tarrytown, NY 10591 USA
[4] Univ Agr & Forestry, Inst Appl Microbiol, A-1190 Vienna, Austria
关键词
D O I
10.1128/JVI.75.22.10906-10911.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS), in combination with proteolytic. protection assays, has been used to identify the functional epitope on human immunodeficiency virus envelope glycoprotein gp41 for the broadly neutralizing and-gp41 human monoclonal antibody 2F5. In this protection assay-based procedure, a soluble gp140 protein with a stabilizing intermolecular disulfide bond between the gp120 and gp41 subunits (SOS gp140) was affinity bound to immobilized 2F5 under physiological; conditions. A combination of proteolytic enzymatic cleavages was then performed to remove unprotected residues. Residues of SOS gp140 protected by their binding to 2F5 were then identified based on their molecular weights as determined by direct MALDI-MS of the immobilized antibody beads. The epitope, NEQELLELDKWASLWN, determined by this MALDI-MS protection assay approach consists of 16 amino acid residues near the C terminus of gp41. It is significantly longer than the ELDKWA core epitope previously determined for 2F5 by peptide enzyme-linked immunosorbent. assay. This new knowledge of the structure of the 2F5 epitope may facilitate the design of vaccine antigens intended to induce antibodies with the breadth and potency of action of the 2F5 monoclonal antibody.
引用
收藏
页码:10906 / 10911
页数:6
相关论文
共 61 条
[1]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[2]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[3]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[4]   Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys [J].
Barouch, DH ;
Craiu, A ;
Santra, S ;
Egan, MA ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Nam, JH ;
Wyatt, LS ;
Lifton, MA ;
Krivulka, GR ;
Nickerson, CE ;
Lord, CI ;
Moss, B ;
Lewis, MG ;
Hirsch, VM ;
Shiver, JW ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2001, 75 (05) :2462-2467
[5]   Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers [J].
Belshe, RB ;
Gorse, GJ ;
Mulligan, MJ ;
Evans, TG ;
Keefer, MC ;
Excler, JL ;
Duliege, AM ;
Tartaglia, J ;
Cox, WI ;
McNamara, J ;
Hwang, KL ;
Bradney, A ;
Montefiori, D ;
Weinhold, KJ .
AIDS, 1998, 12 (18) :2407-2415
[6]   Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding [J].
Binley, JM ;
Ditzel, HJ ;
Barbas, CF ;
Sullivan, N ;
Sodroski, J ;
Parren, PWHI ;
Burton, DR .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (10) :911-924
[7]   A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure [J].
Binley, JM ;
Sanders, RW ;
Clas, B ;
Schuelke, N ;
Master, A ;
Guo, Y ;
Kajumo, F ;
Anselma, DJ ;
Maddon, PJ ;
Olson, WC ;
Moore, JP .
JOURNAL OF VIROLOGY, 2000, 74 (02) :627-643
[8]   GENERATION OF HUMAN MONOCLONAL-ANTIBODIES AGAINST HIV-1 PROTEINS - ELECTROFUSION AND EPSTEIN-BARR-VIRUS TRANSFORMATION FOR PERIPHERAL-BLOOD LYMPHOCYTE IMMORTALIZATION [J].
BUCHACHER, A ;
PREDL, R ;
STRUTZENBERGER, K ;
STEINFELLNER, W ;
TRKOLA, A ;
PURTSCHER, M ;
GRUBER, G ;
TAUER, C ;
STEINDL, F ;
JUNGBAUER, A ;
KATINGER, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) :359-369
[9]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[10]   Why do we not have an HIV vaccine and how can we make one? [J].
Burton, DR ;
Moore, JP .
NATURE MEDICINE, 1998, 4 (05) :495-498